ReviewOncotarget2017
Treatment of hepatocellular carcinoma with portal vein tumor thrombus: advances and challenges.
Review in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 80 citations in OpenAlex.
- Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2020Trial
- Novel Strategies for the Management of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Review.Journal of gastrointestinal cancer · 2026Review
- AI-Driven Radiomics Assisted Prognostic Modeling for Hepatocellular Carcinoma with Portal Vein Invasion: A Retrospective Study.Biomedicines · 2026Article
- Clinical significance of transjugular intrahepatic portosystemic shunting for hepatocellular carcinoma complicated with portal hypertension.Journal of gastrointestinal oncology · 2025Article
- Anxiety is a risk prognosis factor for hepatocellular carcinoma with portal vein tumor thrombus who underwent hepatic arterial infusion chemotherapy: a propensity score-matching cohort study.World journal of surgical oncology · 2025Article
- Article
- Combined radiation and immune checkpoint inhibitor therapy for metastatic or recurrent hepatocellular carcinoma: a real-world study of 108 patients.Frontiers in immunology · 2025Article
- Portal vein tumor thrombosis in hepatocellular carcinoma patients: Is it the end?Liver research (Beijing, China) · 2024Review
- Surgical outcome and risk scoring to predict survival after hepatic resection for hepatocellular carcinoma with portal vein tumor thrombosis.Annals of hepato-biliary-pancreatic surgery · 2024Article
- A Machine Learning Model Based on Counterfactual Theory for Treatment Decision of Hepatocellular Carcinoma Patients.Journal of hepatocellular carcinoma · 2024Article
- TACE combined with portal particle implantation in a case of stage IIIa primary hepatocellular carcinoma treated with sequential anlotinib.Journal of contemporary brachytherapy · 2023Article
- Circular RNA circDLG1 contributes to HCC progression by regulating the miR-141-3p/WTAP axis.Functional & integrative genomics · 2023Article
- Effectiveness and Safety of the PD-1 Inhibitor Lenvatinib Plus Radiotherapy in Patients with HCC with Main PVTT: Real-World Data from a Tertiary Centre.Journal of hepatocellular carcinoma · 2023Article
- The Feasibility of TACE Combined with TKIs Plus PD-1 Antibody for Advanced HCC.Journal of hepatocellular carcinoma · 2023Article
- A study of the clinical profile, predictors, prognostic features, and survival of patients with hepatocellular carcinoma having macroscopic portal vein tumor thrombosis.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2022Article
- Lenvatinib plus TACE with or without pembrolizumab for the treatment of initially unresectable hepatocellular carcinoma harbouring PD-L1 expression: a retrospective study.Journal of cancer research and clinical oncology · 2022Article
- Treatments of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: Current Status and Controversy.Journal of clinical and translational hepatology · 2022Review
- CharacterizingJournal of oncology · 2022Article
- Classification and Prognostic Characteristics of Hepatocellular Carcinoma Based on Glycolysis Cholesterol Synthesis Axis.Journal of oncology · 2022Article
- Construction of HBV gene-related prognostic and diagnostic models for hepatocellular carcinoma.Frontiers in genetics · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Portal vein tumor thrombus is a frequent, challenging complication in hepatocellular carcinoma. Hepatocellular carcinoma patients with portal vein tumor thrombus may show worse liver function, less treatment tolerance and worse prognosis than patients without portal vein tumor thrombus, and they may be at higher risk of comorbidity related to portal hypertension. Western and some Asian guidelines stratify hepatocellular carcinoma with portal vein tumor thrombus together with metastatic hepatocellular carcinoma and therefore recommend only palliative treatment with sorafenib or other systemic agents. In recent years, more treatment options have become available for hepatocellular carcinoma patients with portal vein tumor thrombus, and an evidence-based approach to optimizing disease management and treatment has become more widespread. Nevertheless, consensus policies for managing hepatocellular carcinoma with portal vein tumor thrombus have not been established. This comprehensive literature review, drawing primarily on studies published after 2010, examines currently available management options for patients with hepatocellular carcinoma and portal vein tumor thrombus.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.